# Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

> **NCT03768219** · PHASE1 · TERMINATED · sponsor: **Aptevo Therapeutics** · enrollment: 85 (actual)

## Conditions studied

- Psoriasis
- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** APVO210
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03768219
- **Lead sponsor:** Aptevo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-18
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768219, "Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03768219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*